Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 11/20 | 0.39 |
| ▸ | EGFR | P00533 | 1/20 | 0.35 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.34 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.34 |
| ▸ | MAP3K9 | P80192 | 1/20 | 0.33 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.33 |
| ▸ | YTHDC1 | Q96MU7 | 3/20 | 0.32 |
| ▸ | TTK | P33981 | 1/20 | 0.32 |
| ▸ | PDE5A | O76074 | 1/20 | 0.32 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.31 |
| ▸ | IGF1R | P08069 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24944496 | 0.93 | LRRK2 (0.36) | LRRK2EGFRPDCD1CD274YTHDC1 | |
| SCHEMBL30206172 | 0.93 | LRRK2 (0.35) | LRRK2EGFRPDCD1CD274YTHDC1 | |
| Formic Acid SCHEMBL30205591 | 0.90 | LRRK2 (0.35) | LRRK2EGFRPDCD1CD274ALK | |
| SCHEMBL24944188 | 0.85 | IKBKE (0.35) | LRRK2PDCD1CD274ALK | |
| SCHEMBL30801879 | 0.85 | IKBKE (0.35) | LRRK2PDCD1CD274ALK | |
| SCHEMBL31577238 | 0.85 | LRRK2 (0.36) | LRRK2TTK | |
| SCHEMBL30206109 | 0.84 | LRRK2 (0.43) | LRRK2EGFRIGF1RKCNH2 | |
| SCHEMBL29173386 | 0.84 | LRRK2 (0.43) | LRRK2EGFRIGF1RKCNH2 | |
| SCHEMBL24944494 | 0.84 | LRRK2 (0.42) | LRRK2EGFRMAP3K9MKNK2ALK | |
| SCHEMBL29173415 | 0.83 | CCNC (0.42) | LRRK2EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4373817-B1 | SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2025-05-21 | — | — | EP | disclosed |
| EP-4373817-A1 | SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER | Astrazeneca AB (SE) | 2024-05-29 | — | — | EP | disclosed |
| WO-2023001794-A1 | SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2023-01-26 | — | — | WO | disclosed |